Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L23a pseudogene 88 (RPL23AP88) is a processed pseudogene, meaning it resembles the ribosomal protein L23a gene but does not encode a functional protein. Pseudogenes like RPL23AP88 generally lack protein-coding capacity and are not considered classic therapeutic targets, receptors, enzymes, or similar druggable entities. There is no evidence that RPL23AP88 is involved in canonical biological functions, diseases, or drug interactions. Its primary classification is as a non-functional genomic sequence originating from the ribosomal protein L23a gene family[1]. \n\nNote: It is possible you meant another member of the ribosomal protein L23a pseudogene family, such as RPL23AP53, which has some described associations with cancer biology, but RPL23AP88 itself is specifically classified as a pseudogene and not a protein-coding or functional therapeutic target[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L23a pseudogene 88 (RPL23AP88).